akash.verma@cenmed.com
(732) 447-1115-
E174249-5mgProduct Application：ELECLAZINE is a late sodium current inhibitor and a phase II agent with demonstrated pre-clinical anti-ischemic and antiarrhythmic properties. -
E174249-25mgProduct Application：ELECLAZINE is a late sodium current inhibitor and a phase II agent with demonstrated pre-clinical anti-ischemic and antiarrhythmic properties. -
E174249-250mgProduct Application：ELECLAZINE is a late sodium current inhibitor and a phase II agent with demonstrated pre-clinical anti-ischemic and antiarrhythmic properties. -
E174249-100mgProduct Application：ELECLAZINE is a late sodium current inhibitor and a phase II agent with demonstrated pre-clinical anti-ischemic and antiarrhythmic properties. -
-
E126576-5mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-50mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-25mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-250mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-1mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-1gElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical -
E126576-10mgElacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical
